Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.43 |
| ▸ | ACE | P12821 | 6/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8026913 | 1.00 | MME (0.43) | MMEACENPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8026918 | 1.00 | MME (0.43) | MMEACENPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8027558 | 0.87 | MME (0.53) | MMEACENPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8027559 | 0.87 | MME (0.53) | MMEACENPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8027297 | 0.86 | MME (0.44) | MMEACEALDH1A1SMN1; SMN2 | |
| SCHEMBL8027302 | 0.86 | MME (0.44) | MMEACEALDH1A1SMN1; SMN2 | |
| SCHEMBL27464505 | 0.86 | MME (0.44) | MMEACEALDH1A1SMN1; SMN2 | |
| SCHEMBL8027100 | 0.81 | MME (0.49) | MMEACEALDH1A1 | |
| SCHEMBL8027105 | 0.81 | MME (0.49) | MMEACEALDH1A1 | |
| SCHEMBL8451445 | 0.76 | MME (0.36) | MMEACEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1138321-A | 1, 3-dialkyl urea derivative with hydrocarbon group | SANTAN PHARMACEUTICAL CO LTD (JP) | 1996-12-18 | — | — | CN | disclosed |